Sanofi Signs €1 Billion Share Buyback Mandate

Sanofi, a global biopharma company, announced the signing of a mandate to repurchase its own shares up to €1 billion. The mandate was finalized on February 2, 2026, with an investment service provider. The buyback program is set to run from February 3 to December 31, 2026. This strategic move allows Sanofi to consolidate its market position and optimize its capital structure.

The authorization for this transaction is subject to renewal at the Annual General Meeting on April 29, 2026. This buyback initiative reflects Sanofi's confidence in its value proposition and financial health, aiming to benefit shareholders by potentially enhancing earnings per share and return on equity.